Trastuzumab, a monoclonal antibody directed against HER2, the product of the c-erbB2 proto-oncogene, represents a major step forward in the treatment of the subset of 20 to 30% human breast cancers carrying this genetic abnormality[1-4]. Here, ERBB2 is linked to breast carcinoma.